Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026)
Viatris (VTRS) posted Liabilities and Shareholders Equity of $35.0 billion for Q2 2026, down 4.86% on a QoQ basis from $36.8 billion in Q1 2026, and down 8.77% year-over-year from $38.4 billion in Q2 2025.
Analysis
Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Viatris has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $35.0 billion in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 8.77% year-over-year to $35.0 billion in Q2 2026; TTM through Jun 2026 was $147.0 billion, a 9.9% decrease from a year earlier, with the FY2025 full-year figure at $37.2 billion, down 10.38% from the prior year.
- Liabilities and Shareholders Equity was $35.0 billion for Q2 2026 at Viatris, down from $36.8 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $53.5 billion in Q1 2022, with the low at $35.0 billion in Q2 2026.
- Average Liabilities and Shareholders Equity over 5 years is $44.5 billion, with a median of $46.3 billion recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity increased 0.16% in 2023, then dropped 18.73% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $50.0 billion in 2022, then slipped by 4.67% to $47.7 billion in 2023, then slipped by 12.97% to $41.5 billion in 2024, then dropped by 10.38% to $37.2 billion in 2025, then decreased by 5.78% to $35.0 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $35.0 billion (Q2 2026), $36.8 billion (Q1 2026), and $37.2 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 39.86 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 35.04 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 6.08 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 3.78 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 24.79 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 1.59 Bn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 1.49 Bn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 1.74 Bn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 75.75 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 25.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35.04 Bn |
| Mar 31, 2026 | 36.83 Bn |
| Dec 31, 2025 | 37.19 Bn |
| Sep 30, 2025 | 37.92 Bn |
| Jun 30, 2025 | 38.41 Bn |
| Mar 31, 2025 | 38.47 Bn |
| Dec 31, 2024 | 41.50 Bn |
| Sep 30, 2024 | 44.75 Bn |
| Jun 30, 2024 | 45.33 Bn |
| Mar 31, 2024 | 47.34 Bn |
| Dec 31, 2023 | 47.69 Bn |
| Sep 30, 2023 | 48.74 Bn |
| Jun 30, 2023 | 48.70 Bn |
| Mar 31, 2023 | 49.29 Bn |
| Dec 31, 2022 | 50.02 Bn |
| Sep 30, 2022 | 48.66 Bn |
| Jun 30, 2022 | 51.13 Bn |
| Mar 31, 2022 | 53.47 Bn |
| Dec 31, 2021 | 54.84 Bn |
| Sep 30, 2021 | 56.07 Bn |